This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Transformed Interoperable Smart Pumps Improve Patient Compliance And Market Potential

MOUNTAIN VIEW, Calif., Oct. 1, 2013 /PRNewswire/ -- Advancements in pump technology, especially in terms of specialized functionalities such as infusion rate detection and dosage mismatch alerts, sustain the mature, replacement-intensive infusion pumps market in the U.S. In particular, the ambulatory and insulin pump segments are poised for significant growth despite reimbursement restrictions and government initiatives to lower overall healthcare costs.

New analysis from Frost & Sullivan's ( http://www.medtech.frost.com) Strategic Analysis of the US Infusion Pumps Market research finds the market earned revenue of $3.17 billion in 2012 and estimates this to reach $4.29 billion in 2019. The analysis covers general infusion pumps (volumetric, syringe, ambulatory, enteral pumps and infusion pump accessories) and insulin infusion pumps.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Since current smart pumps failed to make meaningful improvements in patient safety due to a lack of additional interfaces and software capabilities, market participants are looking to develop wireless, user-friendly smart pumps to enhance patient compliance and facilitate homecare use," said Frost & Sullivan Healthcare Research Analyst Swathi Allada. "This widens the scope of the infusion pumps market in the U.S."

However, the safety and efficacy of these new technologies are a concern owing to the alarming increase in errors and product recalls, prompting several hospitals to postpone purchases. In addition, the launch of advanced infusion pumps is delayed as regulatory authorities, including the Food and Drug Administration (FDA), take stringent steps to assess the safety parameters of infusion pumps.

The FDA is expected to mandate manufacturers to submit design validations prior to premarket approval. In response, several manufacturers are focusing on product redesign to meet international standards for reliability and risk management.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,842.85 -85.35 -0.48%
S&P 500 2,074.43 -15.03 -0.72%
NASDAQ 4,906.1140 -33.2130 -0.67%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs